Monoamine oxidase inhibitors (also called MAO inhibitors or MAOIs) block the actions of monoamine oxidase enzymes.
Monoamine oxidase enzymes are responsible for breaking down neurotransmitters such as dopamine, norepinephrine, and serotonin in the brain. Historically, experts have associated low levels of these three neurotransmitters with depression, although this may not be the cause of depression. MAOIs increase the concentration of these three neurotransmitters by blocking the effects of monoamine oxidase enzymes.
MAOIs are typically only used when other antidepressants have proven ineffective, because they have a higher risk of drug interactions than standard antidepressants and can also interact with certain types of food such as aged cheeses and cured meats. They also tend to have more side effects than standard antidepressants and may cause a withdrawal syndrome on discontinuation.
MAOIs may be used to treat the symptoms of depression, such as sadness, anxiety, or worry, that have not responded to other antidepressants. They should not be used to treat depression associated with bipolar disorder because they may precipitate manic symptoms.
There are some other drugs that also inhibit monoamine oxidase enzymes (in addition to having other properties), but are not used for the treatment of depression. These drugs should not be taken within 14 days of another MAOI nor with food or beverages that have a high tyramine content. Some resources may not list these drugs as MAOIs even though they inhibit monoamine oxidase enzymes. Examples include:
All three MAOIs (isocarboxazid, phenelzine and tranylcypromine), available in the U.S. and used for the treatment of depression, are irreversible inhibitors of the enzyme monoamine oxidase. Irreversible means that the body must regenerate new monoamine oxidase enzymes to resume previous levels of enzymatic activity. This can take weeks, which means that the effects of MAOIs persist long after the drugs have been cleared from the body.
Phenelzine may be more likely to cause sedation and weight gain than isocarboxazid or tranylcypromine.
Generic name | Brand name examples |
---|---|
isocarboxazid | Marplan |
phenelzine | Nardil |
tranylcypromine | Parnate |
When taken at the recommended dosage, MAOIs are considered safe. However, they are potentially fatal in overdose and have also been associated with a few serious, potentially fatal, side effects such as:
MAOIs should not be given to people with heart disease or high blood pressure, or to people with pheochromocytoma. They should be discontinued 10 days prior to elective surgery.
One of the more common side effects experienced when initiating treatment with MAOIs is low blood pressure when moving from a sitting to a standing position (called orthostatic hypotension). In most people this can be managed by slowly increasing the dosage of the medication, giving split doses, and increasing fluid intake.
Other common side effects when starting therapy include:
Insomnia may be helped by not giving doses too late in the evening.
Side effects that tend to occur with regular, long-term therapy include:
Paresthesias may be helped by pyridoxine supplementation.
For a complete list of side effects, please refer to the individual drug monographs.
Name | Updated |
---|---|
Isocarboxazid (Isocarboxazid [ eye-so-kar-box-a-zid ]) | 14-Aug-2023 |
Phenelzine (Phenelzine [ fen-el-zeen ]) | 14-Aug-2023 |
Tranylcypromine (Tranylcypromine [ tran-il-sip-roe-meen ]) | 12-Aug-2023 |
Selegiline (transdermal) (Selegiline (transdermal) [ se-le-ji-leen ]) | 12-Aug-2023 |
Selegiline (Selegiline (oral) [ se-le-ji-leen ]) | 12-Aug-2023 |
Zelapar (Selegiline (oral) [ se-le-ji-leen ]) | 14-Jul-2023 |
Parnate (Tranylcypromine [ tran-il-sip-roe-meen ]) | 13-Jul-2023 |
Nardil (Phenelzine [ fen-el-zeen ]) | 13-Jul-2023 |
Marplan (Isocarboxazid [ eye-so-kar-box-a-zid ]) | 13-Jul-2023 |
Emsam (Selegiline (transdermal) [ se-le-ji-leen ]) | 13-Jul-2023 |
Eldepryl (Selegiline (oral) [ se-le-ji-leen ]) | 13-Jul-2023 |